ENSC VS ACON Stock Comparison

Performance

ENSC
10/100

ENSC returned -96.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ACON
10/100

ACON returned -64.22% in the last 12 months. Based on SPY's performance of -10.87%, its performance is below average giving it a score of 10 of 100.

Technicals

ENSC
25/100

ENSC receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

ACON
21/100

ACON receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

ENSC
33/100

ENSC has missed earnings 3 times in the last 20 quarters.

ACON
100/100

ACON has missed earnings 1 times in the last 20 quarters.

Profit

ENSC
27/100

Out of the last 20 quarters, ENSC has had 8 profitable quarters and has increased their profits year over year on 2 of them.

ACON
10/100

Out of the last 11 quarters, ACON has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ENSC
50/100

ENSC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

ACON
47/100

ACON has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Ensysce Biosciences, Inc. Common Stock Summary

Nasdaq / ENSC

Healthcare

Biotechnology

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Aclarion, Inc. Common Stock Summary

Nasdaq / ACON

Healthcare

Medical - Healthcare Information Services

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Power up your portfolio